AbbVie (NYSE: ABBV) has announced a partnership with US-based Gilgamesh Pharmaceuticals to develop a portfolio of next-generation therapies targeting psychiatric disorders. Under the agreement, Gilgamesh will receive an upfront payment of USD 65 million, with the potential for up to USD 1.95 billion in milestone payments and sales royalties. AbbVie will take the lead on development and commercialization efforts.
The collaboration aims to discover novel neuroplastogens, which are next-generation psychedelic compounds with significant clinical potential in the treatment of mental health disorders. These compounds are designed to have minimal psychoactive effects, offering a potential advancement in psychiatric treatment.- Flcube.com
